3-[2-{2-allyl-4-(2-ethoxycarbonylethyl)-phenyl}ethynyl]quinuclidin-3-ol | 166957-84-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: 3-[2-{2-allyl-4-(2-ethoxycarbonylethyl)-phenyl}ethynyl]quinuclidin-3-ol
• 英文别名: 3-[3-Allyl-4-(3-hydroxy-1-aza-bicyclo[2.2.2]oct-3-ylethynyl)-phenyl]-propionic acid ethyl ester；ethyl 3-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]-3-prop-2-enylphenyl]propanoate
• CAS: 166957-84-2
• 化学式: C₂₃H₂₉NO₃
• 分子量: 367.488
• InChiKey: FBPJEWKDFUWVKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[2-{2-allyl-4-(2-ethoxycarbonylethyl)-phenyl}ethynyl]quinuclidin-3-ol 在 氨 作用下， 以 甲醇 为溶剂， 反应 40.0h， 生成 3-[3-Allyl-4-(3-hydroxy-1-aza-bicyclo[2.2.2]oct-3-ylethynyl)-phenyl]-propionamide
  参考文献：
  名称：

  Novel optimised quinuclidine squalene synthase inhibitors

  摘要：

  Optimised quinuclidine squalene synthase (SQS) inhibitors are reported; 3-[2-(2-allyl-4-(2-ethoxy carbonylethyl)phenyl)ethynyl]quinuclidin-3-ol 1c, is a potent inhibitor of rat (KI = 6 nM) and human (KI = 43 nM) microsomal SQS; the oral ED(50) of 1c, for the inhibition of rat cholesterol biosynthesis was 1.3+/-0.45 mg/kg and for the R-enantiomer 1m, 0.8+/-0.2 mg/kg, with the corresponding R-carboxylic acid 6a, being 0.9+/-0.25 mg/kg. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)00053-x
• 作为产物：
  描述：

  对羟基苯丙酸乙酯 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 、 三乙胺 作用下， 以 二苯醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 生成 3-[2-{2-allyl-4-(2-ethoxycarbonylethyl)-phenyl}ethynyl]quinuclidin-3-ol
  参考文献：
  名称：

  Novel optimised quinuclidine squalene synthase inhibitors

  摘要：

  Optimised quinuclidine squalene synthase (SQS) inhibitors are reported; 3-[2-(2-allyl-4-(2-ethoxy carbonylethyl)phenyl)ethynyl]quinuclidin-3-ol 1c, is a potent inhibitor of rat (KI = 6 nM) and human (KI = 43 nM) microsomal SQS; the oral ED(50) of 1c, for the inhibition of rat cholesterol biosynthesis was 1.3+/-0.45 mg/kg and for the R-enantiomer 1m, 0.8+/-0.2 mg/kg, with the corresponding R-carboxylic acid 6a, being 0.9+/-0.25 mg/kg. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(97)00053-x

文献信息

• HETEROCYCLIC DERIVATIVES
  申请人：ZENECA LIMITED

  公开号：EP0696284A1

  公开（公告）日：1996-02-14
• [EN] HETEROCYCLIC DERIVATIVES<br/>[FR] DERIVES HETEROCYCLIQUES
  申请人：ZENECA LIMITED

  公开号：WO1994025459A1

  公开（公告）日：1994-11-10

  (EN) Compounds of formula (I) wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 are joined together so that CR1-CR2 is a double bond; X is selected from -CH2CH2-, -CH=CH-, -C$m(Z)C-, -CH2O-, -OCH2-, CH2NH-, -NHCH2-, -CH2CO-, -COCH2-, -CH2S(O)n- and -S(O)nCH2- (wherein n is 0, 1 or 2); Ar is phenyl which bears one or more substituents independently selected from the groups (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyl, (1-6C) alkylcarbamoyl, di-[(1-6C)alkyl]carbamoyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oximes, (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl when substituted by one or more groups selected from (1-6C)alkoxycarbonyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oxime derivatives, (1-6C)alkanoylamino, (1-6C)alkanoyloxy, (1-6C)alkanoyloxy(1-6C)alkyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di[(1-6C)alkyl]carbamoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxy, (2-6C)alkenyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, phenyl, phenoxy, cyano, nitro, hydroxy and carboxy; and wherein Ar may bear further substituents; and their pharmaceutically acceptable salts inhibit squalene synthese and are hence useful in lowering cholesterol levels in blood plasma. Processes for preparing compounds of formula (I) are also referred to as well as pharmaceutical compositions containing them and their use in medicine.(FR) L'invention concerne des composés de la formule (I) dans laquelle R1 représente hydrogène ou hydroxy; R2 représente hydrogène; ou R1 et R2 sont reunis de sorte que CR1-CR2 forme une double liaison; X est sélectionné à partir de -CH2CH2-, -CH=CH-, -C$m(Z)C-, -CH2O-, -OCH2-, CH2NH-, -NHCH2-, -CH2CO-, -COCH2-, -CH2S(O)n- and -S(O)nCH2- (où n vaut 0, 1 ou 2); Ar représente phényle qui porte un ou plusieurs substituants indépendamment sélectionnés dans les groupes (1-6)alkyle, (2-6C)alcényle, (2-6C)alkynyle, (1-6C)alcoxy, (1-6C)alcoxycarbonyle, (1-6C)alcoxycarbonyl(1-6C)alkyle, (1-6C)alcoxy(1-6C)alkyle, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, carbamoyle, (1-6C)alkylcarbamoyle, di-[(1-6C)alkyl]carbamoyle, (1-6C)alcanoyle et des dérivés d'oxime de ceux-ci, et des éthers O-(1-6C)alkyl de ces oximes, (1-6C)alkylthio, (1-6C)alkylsulphinyle et (1-6C)alkylsulphonyle lorsqu'ils sont substitués par un ou plusieurs groupes sélectionnés à partir de (1-6C)alcoxycarbonyle, (1-6C)alcanoyle et des dérivés d'oxime de ceux-ci, et des éthers O-(1-6C)alkyle de ces dérivés d'oxime, (1-6C)alcanoylamino, (1-6C)alcanoyloxy, (1-6C)alcanoyloxy(1-6C)alkyle, carbamoyle, N-(1-6C)alkylcarbamoyle, N,N-di[(1-6C)alkyl]carbamoyle, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alcoxy, (2-6C)alcényloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyle, (1-6C)alkylsulphonyle, halogéno(1-6C)alkyle, (2-6C)alcényle, (2-6C)alkynyle, phényle, phénoxy, cyano, nitro, hydroxy et carboxy; et où Ar peut porter d'autres substituants; et leurs sels pharmaceutiquement acceptables inhibent la synthase squaléne et sont par conséquent utiles dans la réduction des taux de cholestérol dans le plasma sanguin. L'invention concerne également des procédés de préparation des composés de la formule (I) et des compositions pharmaceutiques les contenant ainsi que leur utilisation en médicine.
• Novel optimised quinuclidine squalene synthase inhibitors
  作者：George R. Brown、Alan J. Foubister、Susan Freeman、Fergus McTaggart、Donald J. Mirrlees、Alan C. Reid、Graham J. Smith、Melvyn J. Taylor、Douglas A. Thomason、Paul R.O. Whittamore

  DOI：10.1016/s0960-894x(97)00053-x

  日期：1997.3

  Optimised quinuclidine squalene synthase (SQS) inhibitors are reported; 3-[2-(2-allyl-4-(2-ethoxy carbonylethyl)phenyl)ethynyl]quinuclidin-3-ol 1c, is a potent inhibitor of rat (KI = 6 nM) and human (KI = 43 nM) microsomal SQS; the oral ED(50) of 1c, for the inhibition of rat cholesterol biosynthesis was 1.3+/-0.45 mg/kg and for the R-enantiomer 1m, 0.8+/-0.2 mg/kg, with the corresponding R-carboxylic acid 6a, being 0.9+/-0.25 mg/kg. (C) 1997 Elsevier Science Ltd. All rights reserved.